Research programme: P2 receptor modulators - Inspire Pharmaceuticals

Drug Profile

Research programme: P2 receptor modulators - Inspire Pharmaceuticals

Alternative Names: INS 117284; INS 48506; INS 48821; INS 48824; Non-P2Y2 receptor modulators - Inspire; P2X3 receptor antagonists - Inspire; P2Y12 receptor antagonists - Inspire

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Merck & Co
  • Class
  • Mechanism of Action Purinergic P2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain; Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
  • 16 May 2011 Inspire Pharmaceuticals has been acquired by Merck & Co
  • 25 Mar 2009 Preclinical development is ongoing for Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top